Shares in Schott Pharma saw a significant surge in value as it made its debut on the Frankfurt Stock Exchange. At 0851 GMT on Thursday, shares were trading at EUR29.96, representing an impressive 11% increase from the IPO price of EUR27.00.
The German company, which specializes in delivery systems for injectable drugs, achieved a market capitalization of 4.1 billion euros ($4.31 billion) based on its IPO price. The IPO raised gross proceeds of EUR935 million.
Analysts believe the timing for the IPO couldn’t be better, noting Schott Pharma’s consistent success in recent years. Konstantin Oldenburger, an analyst at CMC Markets, praised Schott Pharma for its strong performance.
Another notable development surrounding the IPO is Qatar Holding’s participation. The investment company acquired a 4.9% stake in Schott Pharma by purchasing 7.4 million shares for EUR200 million. As a result, glassmaker Schott will continue to hold a 77% stake in the pharmaceutical company.
Schott Pharma operates in a niche market with high entry barriers and has gained a significant investor in Qatar Holding. This new partnership is expected to contribute to the company’s continuous growth and sustainability objectives.
Overall, with a successful IPO under its belt, Schott Pharma aims to further support the expansion of its own business as well as the growth of the entire group.
